| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 23, 2021 | BCRX Biocryst Pharmaceuticals Inc | Doyle Anthony70 | Chief Financial Officer | Buy | 35,258 | $12.48 | $440,019.84 | +60.3% | +43.5% | +0.2% | |
| Nov 23, 2021 | IRWD Ironwood Pharmaceuticals Inc | McCourt Thomas A66 | Chief Executive Officer | Sell | 52,644 | $11.58 | $609,617.52 | -7.8% | -6.5% | -0.4% | |
| Nov 23, 2021 | ZTS Zoetis Inc. | Lagano Roxanne70 | Executive Vice President | Sell | 1,315 | $223.09 | $293,363.35 | -6.5% | -14.9% | -32.2% | |
| Nov 23, 2021 | IRWD Ironwood Pharmaceuticals Inc | Shetzline Michael67 | CMO,SVP,Head-res&Drug | Sell | 13,776 | $11.58 | $159,526.08 | -7.0% | -6.5% | -0.4% | |
| Nov 23, 2021 | IRWD Ironwood Pharmaceuticals Inc | Rickard Jason65 | SVP, Chief Operating Officer | Sell | 17,193 | $11.58 | $199,094.94 | -2.4% | -6.5% | -0.4% | |
| Nov 23, 2021 | CPIX Cumberland Pharmaceuticals Inc | Hamm John M. | Chief Financial Officer | Buy | 3,800 | $2.35 | $8,930.00 | +126.7% | +31.5% | -0.9% | |
| Nov 23, 2021 | IRWD Ironwood Pharmaceuticals Inc | Silver Ronald68 | Principal Accounting Officer | Sell | 1,462 | $11.58 | $16,929.96 | -1.2% | -6.5% | -0.4% | |
| Nov 22, 2021 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 3,083 | $200.42 | $617,894.86 | -96.0% | -2.6% | +36.2% | |
| Nov 22, 2021 | AMPH Amphastar Pharmaceuticals, Inc. | Prins Richard K61 | Director | Sell | 5,000 | $21.22 | $106,100.00 | -10.0% | +23.8% | +36.5% | |
| Nov 18, 2021 | TXMD Therapeuticsmd, Inc. | Collins Cooper C. | Director | Buy | 1,000,000 | $0.58 | $578,500.00 | +80.8% | -55.2% | -82.7% | |
| Nov 18, 2021 | ORGO Organogenesis Holdings Inc. | Gn 2016 Organo 10-Year Grat U/a/d September 30, 2016 | 10% Owner | Buy | 25,000 | $9.93 | $248,250.00 | - | -21.2% | -73.8% | |
| Nov 18, 2021 | ORGO Organogenesis Holdings Inc. | Nussdorf Glenn H75 | Director, 10% Owner | Buy | 25,000 | $9.93 | $248,250.00 | - | -21.2% | -73.8% | |
| Nov 17, 2021 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 3,083 | $201.90 | $622,457.70 | -96.0% | +2.4% | +32.8% | |
| Nov 17, 2021 | ETON Eton Pharmaceuticals, Inc. | Opaleye Management Inc.60 | 10% Owner | Sell | 25,000 | $4.67 | $116,712.50 | -1.0% | -16.8% | -36.3% | |
| Nov 17, 2021 | DVAX Dynavax Technologies Corp | Janssen Robert71 | Senior Vice President | Sell | 89,405 | $17.11 | $1,529,770.90 | -84.4% | -21.5% | -21.6% | |
| Nov 17, 2021 | ORGO Organogenesis Holdings Inc. | Katz Michael W | 10% Owner | Buy | 5,000 | $11.11 | $55,550.00 | +2.4% | -23.8% | -75.3% | |
| Nov 16, 2021 | ETON Eton Pharmaceuticals, Inc. | Opaleye Management Inc.60 | 10% Owner | Sell | 15,438 | $4.85 | $74,877.11 | -0.3% | -23.1% | -35.9% | |
| Nov 15, 2021 | ELAN Elanco Animal Health Inc | Hoover R David50 | Director | Buy | 5,000 | $31.79 | $158,934.50 | +5.6% | -21.9% | -60.4% | |
| Nov 15, 2021 | BCRX Biocryst Pharmaceuticals Inc | Abercrombie George B68 | Director | Sell | 5,000 | $12.27 | $61,350.00 | -100% | +50.0% | +11.5% | |
| Nov 15, 2021 | EBS Emergent Biosolutions Inc. | Lindahl Richard S | EVP, Chief Financial Officer | Buy | 3,000 | $37.46 | $112,380.00 | +8.1% | +17.7% | -64.9% | |
| Nov 15, 2021 | LNTH Lantheus Holdings, Inc. | Sabens Andrea47 | Chief Accounting Officer | Sell | 1,242 | $30.47 | $37,843.74 | -1.9% | -4.5% | +98.2% | |
| Nov 15, 2021 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairman &CEO | Sell | 3,083 | $203.45 | $627,236.35 | -96.0% | -1.1% | +26.4% | |
| Nov 15, 2021 | INM Inmed Pharmaceuticals Inc. | Johnson Shane Aaron | SVP, Gm Of Baymedica LLC | Buy | 5,000 | $1.37 | $6,845.00 | +1.8% | -14.9% | -91.7% | |
| Nov 12, 2021 | PBH Prestige Consumer Healthcare Inc. | Lombardi Ronald M.52 | Chief Executive Office | Sell | 52,367 | $62.78 | $3,287,600.26 | -24.7% | -6.7% | -8.2% | |
| Nov 12, 2021 | PFE Pfizer Inc | Hwang Angela | Group President | Sell | 26,170 | $49.60 | $1,298,001.78 | -30.9% | +2.5% | -1.2% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.